Monday, November 12, 2012

Spectrum Pharma's partner Topotarget maintains primary end point met in Belief trial

Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

Here is Topotarget's conf call from today
Slide 4 of IR presentation has the below

BELIEF meets primary endpoint 
Primary endpoint – objective response rate of at least 20% – has been met
• Trial data being further analyzed and expected communicated Q4 2012
• Anticipated filing for belinostat NDA mid-2013
• If FDA accepts filing of belinostat NDA, Topotarget entitled to 1 million SPPI shares and double-digit million USD cash payment
• If FDA approves belinostat, Topotarget to receive double-digit million USD 
cash payment

No comments:

Post a Comment